Your browser doesn't support javascript.
loading
Clinical efficacy of decitabine combined with modified CAG regimen for relapsed-refractory acute myeloid leukemia with AML1-ETO⁺ / 中国实验血液学杂志
Journal of Experimental Hematology ; (6): 1245-1250, 2014.
Artigo em Chinês | WPRIM | ID: wpr-340520
ABSTRACT
This study was aimed to investigate the clinical characteristics of relapsed-refractory acute myeloid leukemia (AML) with AML1-ETO⁺, and its therapeutic efficacy and side effects when decitabine combined with modified CAG regimen was used. Clinical data of 5 cases of AML with AML1-ETO⁺ from January 2013 to Agust 2013 were analyzed retrospectively. The analyzed data included age, sex, initial symptoms, peripheral blood and bone marrow characteristics. Meanwhile, the therapeutic effecacy and side effects of decitabine combined with modified CAG regimen were evaluated. The 5 patients were with median age of 35 (17-43) years. Among these 5 patients, 2 patients were relapsed and other 3 patients were relapsed-refractory patients, their median white blood cell count was 12.55 (7.8-66.55) × 10⁹/L, median platelets count was 44 (20-72) × 10⁹/L, median hemoglobin level was 110 (77-128) g/L, median lactate dehydrogenase level was 312.9 U/L (123.6-877.8) at the initial diagnosis. The results showed that after decitabine combined with modified CAG regimen was administered, 4 patients achieved complete remission, 1 patient did not achieve remission, the overall remission rate was 80% (4/5). The main side effects of this regimen was myelosuppression, these were no new lung infection and other serious complications, one case without complete remission treated with FLAG once again died of heart failure when being mobilized for transplantation. It is concluded that according to preliminary results of decitabine combined with modified CAG regimen for relapsed and refractory AML patients with AML1-ETO⁺ displays higher remission rate and lower side effects, which worthy to further explore for clinal application.
Assuntos
Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Recidiva / Azacitidina / Aclarubicina / Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas de Fusão Oncogênica / Estudos Retrospectivos / Fator Estimulador de Colônias de Granulócitos / Resultado do Tratamento / Citarabina Tipo de estudo: Estudo observacional Limite: Adolescente / Adulto / Humanos Idioma: Chinês Revista: Journal of Experimental Hematology Ano de publicação: 2014 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Recidiva / Azacitidina / Aclarubicina / Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas de Fusão Oncogênica / Estudos Retrospectivos / Fator Estimulador de Colônias de Granulócitos / Resultado do Tratamento / Citarabina Tipo de estudo: Estudo observacional Limite: Adolescente / Adulto / Humanos Idioma: Chinês Revista: Journal of Experimental Hematology Ano de publicação: 2014 Tipo de documento: Artigo